1. Home
  2. CLNN vs ACET Comparison

CLNN vs ACET Comparison

Compare CLNN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clene Inc.

CLNN

Clene Inc.

HOLD

Current Price

$8.41

Market Cap

73.7M

Sector

Health Care

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.46

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLNN
ACET
Founded
2012
1947
Country
United States
United States
Employees
79
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.7M
77.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CLNN
ACET
Price
$8.41
$8.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$33.75
$48.33
AVG Volume (30 Days)
72.3K
137.9K
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.64
N/A
Revenue Next Year
$19,516.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.28
$0.46
52 Week High
$13.50
$9.05

Technical Indicators

Market Signals
Indicator
CLNN
ACET
Relative Strength Index (RSI) 73.40 61.66
Support Level $7.65 $6.28
Resistance Level $11.00 $8.46
Average True Range (ATR) 0.66 0.51
MACD 0.08 0.03
Stochastic Oscillator 87.07 82.18

Price Performance

Historical Comparison
CLNN
ACET

About CLNN Clene Inc.

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: